Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorAmsterdam UMC, location VUmc
About this trial
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis. The study will evaluate the following items:
1. Disease activity 2. Safety and tolerability of aHSCT 3. Changes in the immune system
Participants will be subjected to frequent visits for five years after treatment with aHSCT. During these visits, clinical testing, evaluation by questionnaires, MRI scans and blood sampling will be performed.
Eligibility criteria
Qualifiers
All patients approved for treatment with aHSCT in the Netherlands in accordance with the Dutch criteria for aHSCT treatment for RRMS
Disqualifiers
Contra-indications for treatment with aHSCT such as known hypersensitivity to the medication used for aHSCT
Clinically relevant comorbidities preventing safe use of medication used for aHSCT
Severe clinical depression
Active addiction to drugs or alcohol
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Amsterdam UMC, location VUmc
Lead sponsor
St. Antonius Hospital
Collaborator
Source ClinicalTrials.gov